MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
AbCellera Biologics (NASDAQ:ABCL)
Organization & Developments: Abcellera
Parents
AbCellera Biologics (NASDAQ:ABCL)
Children
*AI-powered antibody discovery for mRNA vaccine targets.
*The company’s AI-powered antibody discovery platform speeds the otherwise lengthy and grueling process by analyzing the database of natural immune systems to find antibodies that can be developed into drugs.
2020: A trial is under way of the first new antibody medicine developed to treat covid-19_www.technologyreview.com
2020: Eli Lilly and AbCellera Dose First Patients with COVID-19 Antibody in Phase I Study
2020: Eli Lilly and AbCellera Win EUA for COVID-19 Antibody Treatment
2020: Lilly starts second COVID-19 antibody test with partner Junshi Biosciences, eyes combo trials
2022: AbCellera Biologics Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: AbCellera Biologics: Many Reasons To Own This Undervalued Stock_seekingalpha.com
2023: AbCellera expands its multi-target collaboration with Regeneron (NASDAQ:ABCL)
2023: AbCellera's Clinical Carousel: High Risk, Higher Stakes
2024: AbCellera Biologics: Continuing To Expand Partnerships
2024: AbCellera Biologics: Still A Concept Stock
2024: AbCellera: A Waiting Game With High Uncertainty
2024: AbCellera: Victim Of Its Own Success
2026: AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth Outlook
2026: AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity
225: AbCellera: Burning Cash, Searching For 'Blockbusters'_ seekingalpha.com
Jumps
*Key People: Abcellera
Finance & Acquisitions: Abcellera